What the FDA labels say about taking them together
Atazanavir and ethinyl estradiol/ferrous bisglycinate/levonorgestrel
Ethinyl estradiol/ferrous bisglycinate/levonorgestrel's FDA label of January 9, 2025 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name ethinyl estradiol/ferrous bisglycinate/levonorgestrel. The ethinyl estradiol/ferrous bisglycinate/levonorgestrel label: “Human Immunodeficiency Virus (HIV)/ Hepatitis C Virus (HCV) Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors Significant changes (increase or decrease) in the plasma concentrations of estrogen …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the ethinyl estradiol/ferrous bisglycinate/levonorgestrel FDA label on DailyMed (effective January 9, 2025, Lupin Pharmaceuticals, Inc.).
What does the atazanavir label say about ethinyl estradiol/ferrous bisglycinate/levonorgestrel?
Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name ethinyl estradiol/ferrous bisglycinate/levonorgestrel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the ethinyl estradiol/ferrous bisglycinate/levonorgestrel label say about atazanavir?
Ethinyl estradiol/ferrous bisglycinate/levonorgestrel label, drug interactionsHuman Immunodeficiency Virus (HIV)/ Hepatitis C Virus (HCV) Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV/HCV protease inhibitors and non- nucleoside reverse transcriptase inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos) amprenavir/ritonavir, lopinavir/ritonavir, tipranavir/ritonavir, boceprevir, telaprevir, nevirapine and efavirenz] or increase [e.g., indinavir, atazanavir/ritonavir and etravirine]).
Source: FDA drug label (MINZOYA), Lupin Pharmaceuticals, Inc., effective January 9, 2025 (SPL set d5ebd7fa-c388-4619-8dcb-e862e4ce5285), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Ethinyl estradiol/ferrous bisglycinate/levonorgestrel | |
|---|---|---|
| Labeled for | HIV | Birth control |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $3.45 per tablet 28 tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once